• Nontrauma-related factors may be more predominant in the etiology of affective dyscontrol in individuals with borderline personality disorder.
INTRODUCTION
Affective instability is characterized by alterations in the capacity of individuals to regulate and modulate their experience of mood states in terms of intensity, frequency, and stability. Affective instability is a frequent feature of the psychopathology of those carrying a personality disorder diagnosis. In contrast to the disturbances in Axis I mood disorders, such as major depression and bipolar disorder, which are typically more enduring departures from euthymia in the negative or positive direction, the affective dysregulation in Axis II disorders is characterized by markedly unstable affective states that are disturbingly transient and often rapidly reversible, and are more responsive to stimuli in the environment-both inanimate and interpersonal. Emotional reactions to interpersonal precipitants, such as separation, criticism, disappointment, and frustration, may be especially intense. The impairments in the capacity to modify either the intensity or duration of predominantly negative emotional reactions disrupt the execution of one's goals' and result in significant behavioral and interpersonal difficulties. Despite its relative pervasiveness in the disruption of normal functioning in those with a variety of personality disorder difficulties, affective instability is explicitly included as a diagnostic criterion only for borderline personality disorder (BPD).
The earliest writings on the modern concept of personality disorders came from psychodynamic and psychoanalytic scholars 23 who emphasized the relationship of stable affect to the development of self-esteem and the ability to maintain appropriate relationships. Impaired affect regulation was seen not only as a consequence of the disruption of early attachment 4 " but was understood to lead to disturbed attachments in adulthood, because of maladaptive responses to emotionally provocative interactions, and an accompanying unstable sense of self, identity diffusion, and continuing and self-fulfilling problematic interpersonal relationships. Our group has shown in a sample of adult patients with personality disorders, that affective instability is associated with identity disturbance, chronic feelings of emptiness, and suicidality. 7 Empirical data have shown that affective states in adults are known to influence the way in which the world is experienced, encoded, and retrieved from memory. 8 Presumably, this is true in children as well. 9 A child with emotional vulnerability and impaired emotional regulation will be more sensitive and reactive to the inherent frustrations, disruptions, and separations in normal development. Efforts to mitigate these feelings include displays of distress that can range from clinging to tantrums. These can lead to chronic, repetitive, and maladaptive interactional patterns with othersthe key feature of a personality disorder. Intense negative feelings may also affect self-image through the individual's awareness of their own lack of capacity to modulate affect and, therefore, produce enduring feelings of shame, humiliation, and core defectiveness-additional key features of personality disorders. The empirical literature on affective instability in personality disorders, including BPD, is limited but consistent with its presence. Cowdry and colleagues 10 studied patients with BPD, with major depression, with premenstrual syndrome, and normal controls and rated their mood for 14 straight days using visual analog scales. BPD subjects had the most variability in mood and each rating in mood had almost no relationship with the previous day. Levine and colleagues 11 presented data that demonstrated those with BPD had greater intensity of negative emotions, lower levels of emotional awareness, and impaired ability to process mixed emotions as compared with controls.
In a study of hospitalized female BPD patients, the number of borderline traits was positively associated with affect intensity and affect control. 12 A report from Koenigsberg and colleagues 13 on a subset of the current data (60% overlap) that included 152 subjects with personality disorder and 42 with BPD, observed that affective instability in BPD did not involve all affects, but rather involved anger and anxiety and the oscillation between depression and anxiety. BPD diagnosis was significantly related to a measure of affect intensity but when age, gender, and comorbid Axis I disorder were controlled for, the association did not hold.
1 ' Herpertz and colleagues 14 used measures of skin conductance response, heart rate change, and startle response to the viewing of emotionally laden slides, and found that BPD subjects did not show a general hyperresponsivity to environmental events, but rather lower electrodermal responses than a cluster B personality comparison group. The literature provides a somewhat variable picture depending on the measures that are used.
Emotional dysregulation is also the centerpiece of a more recent view of disordered personality, specifically, Linehan and colleagues' 15 treatment-derived view of the etiology of BPD. Recognizing that crucial features of BPD were emotional vulnerability and maladaptive emotion regulation strategies, their treatment approach concentrated on these features, making basic vulnerability and poor regulation key concepts. These problems may be heightened in families that 16 In such environments, the vulnerable individual is not supported in efforts to label emotions, modulate arousal, or tolerate distress. Abuse-physical, sexual, or emotional-in childhood is an extreme form of an invalidating environment.
The vulnerability of the individual with BPD is not yet well understood. Affective instability has been proposed to be a core psychobiologic predisposition 17 and likely involves alterations in the circuitry of emotional regulation that includes regions of the prefrontal cortex, amygdala, hypothalamus, anterior cingulate cortex, hippocampus, insular cortex, and ventral striatum. 18 There exist individual differences in the asymmetry of activation in anterior structures of this pathway, and in particular, the prefrontal cortex, that have been linked to aspects of emotional responsivity, 19 including the return to baseline after an emotional challenge. Prefrontal cortex fibers help dampen negative affect through an inhibitory influence in the amygdala. 20 Whether these observed effects are from genetic parameter settings, environmental influences on the parameter settings, or a combination of these factors is currently unknown and will be difficult to delineate. It may well be that genetic factors are implicated in the impaired capacity to regulate emotional experience, or it may be that experiential and/or environmental factors, such as trauma, impact basic biological mechanisms implicated in emotional experience, or both. The latter could occur early in a child's life when neural pathways are being established, or it occur later when developmental changes that typically require the reorganization of neural pathways occur. In either case, such longstanding alterations may be the mechanism by which affective instability continues to characterize and distress those with personality disorder, and especially those with BPD. Further investigation of the role of environmental influences, especially traumatic influences, is a necessary path of inquiry. 21 One model for the longstanding and detrimental effects of early environmental stress on developing biological processes is provided by the work of Francis and Meaney. 22 Studying rats exposed to early environmental stressors of changed frequency of maternal licking and grooming, and arched back nursing, significant neurophysiologic, neurohormonal, and neuroendocrine changes down to the level of gene expression occurred in the offspring as a direct consequence of environment. These changes affected stress responsivity, as well as components of the circuitry of emotional processing; the amydgala, hippocampus, and prefrontal cortex.
Empirical research from the last 15 years has noted high rates of childhood physical and sexual abuse in patients with BPD 2 "
4 compared with other comparison groups. For BPD, the presence of some type of childhood abusive experience was almost ubiquitous. Zanarini and colleagues 31 found a 91% abuse rate and a 92% rate of emotional or physical neglect in their cohort of BPD subjects. Estimates of the overall rate of childhood sexual abuse in those with BPD range from 40% to 70% compared with an overall rate of childhood sexual abuse for other Axis II patients to be between 19% and 26%. 23 ' 24p26 ' 2831 Severity of sexual abuse and neglect was significantly related to affective symptoms of BPD. 33 This prompted some to consider the possibility that BPD was a form of posttraumatic stress disorder (PTSD), 23 ' 2 and for a subset of BPD patients with extreme childhood abuse, to devise a new nosological entity, complex PTSD." A meta-analytic study 34 of 21 studies comprising 2,414 subjects that examined the relationship between BPD and childhood sexual abuse yielded only a moderate pooled effect size of r=.28. Diagnostic criteria and gender did not have a predictive role on effect size. A negative relationship between sample size and correlation coefficients (r=-.75) was present, suggestive that smaller, less representative studies were associated with larger effect sizes, and consequently weakening the validity of the finding.
There still exists the possibility that childhood sexual abuse is related to only some features of the BPD condition, and since the diagnosis is polythetic, the relationship may not be consistently manifested at the BPD diagnosis level. 36 For example, in BPD, there are several studies that support a relationship between dissociative phenomena and childhood trauma. 36 ' 39 Despite these conceptual suggestions, minimal empirical data exist that examines the relationship of childhood trauma and the core BPD dimension of affective instability.
The study of affective instability has also been hampered by the complexity of the construct and the difficulty of developing measures that validly assess it. The absence of a wide variety of scales to measure the construct has led to reluctance to study the phenomenon empirically. There exist two validated self-report scales that address two of the several aspects of affective instability: affective lability, measured by the Affective Lability Scale (ALS) 40 and affect intensity, assessed by the Affective Intensity Measure (AIM). 41 We sought to examine the relationship between childhood trauma and affective instability, as indexed by these two scales, in patients with personality disorder diagnoses.
METHODS

Participants
The sample consisted of 174 patients with personality disorder (62 females, 112 males) between 18 and 60 years of age (mean±SD=38.4±9.9), meeting criteria for an average of 2.3±1.5 personality disorder diagnoses, 61 of whom met criteria for BPD. Participants were recruited from the Bronx Veterans Affairs Medical Center's and the Mount Sinai Medical Center's Psychiatric Outpatient Clinics in New York City or from referrals from outside mental health professionals or from paid advertisement for a comprehensive study of which we report data from only a part. All subjects received a medical evaluation, which included history, physical and neurologic examination, and laboratory testing. Patients with evidence of serious systemic illness that might affect central nervous system functioning, such as diabetes, hypertension, autoimmune illness, and renal, liver, or cardiac disorders, were excluded. Patients with neurologic impairment or a history of severe head trauma with loss of consciousness were excluded as well. Potential participants were excluded if they met the Diagnostic and Statistical Manual of Mental Disorders, Third Edition-Revised (DSM-III-R) 42 criteria for schizophrenia or any schizophrenia-related psychotic disorder or for bipolar 1 affective disorder. Meeting criteria for past major depressive disorder did not exclude potential participants because this is a common comorbidity in cluster B personality disorders. Patients were free from substance abuse for at least 6 months and did not currently take medication for medical or psychiatric reasons. All participants gave written informed consent after receiving a complete description of the study.
Psychiatric Assessments
Patients completed extensive psychiatric and diagnostic assessment by trained raters, utilizing the Structured Clinical Interview for Axis I disorders 43 and the Structured Interview for DSM III-R Personality Disorder for Axis II disorders 44 (K=.81 for BPD). A consensus was obtained in consultation with a clinical psychologist not otherwise involved in the study.
Measures
Childhood abuse experience was measured using the Childhood Trauma Questionnaire 45 (CTQ), short form, a 28-item self-report questionnaire that assess a broad range of abusive experiences, including childhood sexual, physical and emotional abuse, and physical and emotional neglect. The response format of the items is a five-point Likert scale with options ranging from "never true" to "very often true." The 70-item measure has been shown to have good reliability (Cronbach's oc=0.79-0.94), and good test-retest reliability (0.80-0.83). 46 It yields five subscales: Sexual Abuse (SA), Emotional Abuse (EA), Physical Abuse (PA), Emotional Neglect (EN), and Physical Neglect (PN), as well as a total score. In our sample, coefficient a for the total score was 0.68.
Each participant completed the ALS. 40 ALS items are rated on a four-point scale (0-3) ranging from "very undescriptive" to "very descriptive." The ALS can be scored for six subscales which demonstrate high internal consistency, but we used only the total score. The ALS has been shown to have good internal consistency, suitable test-retest reliability and not to vary substantially by gender. 40 Previously reported data from a subset of those reported here 13 lend support to the construct validity of the measure. Coefficient a in the present sample was 0.97.
Participants also completed the AIM. 41 The AIM is a 40-item self-report measure, with good internal consistency and test-retest reliability and yields a single Total score. It has been validated by a study comparing subjects' AIM scores with ratings by informants 47 as well as a study of the intensity of subjects' emotional reactions to actual life events and self-assessed characteristic reactions to a set of standardized descriptions of life events. 48 In the present sample, coefficient a was 0.91.
Missing Data
Seven subjects had incomplete responses on the CTQ. Our repair strategy was as follows: If at least 80% of the questions were answered for a particular subscale, the mean value of the remaining items was imputed for the missing value, rounded to the closest integer, and scale score computed since the scales are based on sums. Six subjects (two female BPD, two male BPD, and two females with other personality disorder [OPD]), were eliminated from the analyses on the CTQ subscales of EA, PN, and PA since their responses fell below our threshold for imputation.
Data Analysis
Mean differences in continuous variables, such as CTQ, AIM, and ALS scores, were analyzed using student's t-test. Pearson correlations of ALS and AIM were performed, with each other and by diagnosis, gender, and CTQ subscales. Lastly, hierarchical regression analyses using ALS, AIM, and CTQ were conducted to test the interaction of gender and diagnosis in the relationships between the affect variables and the trauma variables.
FINDINGS
The personality disorder diagnoses of the 174 participants were distributed as shown in Table 1 . Since our focus is on affective instability in BPD, we compared those with BPD (35%; n=61) to the remaining 112, whom we refer to as OPD.
The results for the CTQ were somewhat unexpected. The distribution of SA was markedly skewed (55% had the equivalent of a zero) and, therefore, unusable to correlate with the measures of affect. It also suggested that in this sample, at least, sexual abuse was not a pervasive factor for affective instability. The remaining four subscales had appropriate distributions, and each was correlated with ALS and AIM. We adopted a decision rule, which in addition to being statistically significant, dictated that the subscale must account for at least 4% of the variance-that is r needed to be >0.20. Only EA and Total score met this criterion and was carried forward for further analysis. The correlation between EA and ALS was .20 (P=.OO8); for EA and AIM it was .31 (P<.000). The correlations between AIM and the other CTQ subscales were: r=.19 (P=.012) for PA, r=.12 (NS) for PN; r=.07 (NS) for EN and r=.23 (P=.002) for total score. The correlation between ALS and the other CTQ subscales were: r=.01 (NS) for PA, r=.14 (NS) for PN; r=.05 (NS) for EN and r=.15 (NS) for total score. SA had the lowest correlation (r=.43) and EA the highest correlation (r=.71) with CTQ Total item score.
In Table 2 , the means and standard deviations are presented for the total sample and separately for diagnosis, gender, and gender by diagnosis for the affect variables and CTQ EA and Total. The further investigation of the differential pattern of results yielded by gender and diagnosis considered separately and in combination, are presented in Tables 3A-3E which present the Pearson correlations among the affect, trauma, and categorical variables. Patterns of relationship differ across groups with BPD and females demonstrating the most variability. Moreover, the relationship of ALS and AIM to C T Q EA is different as a function of both gender and diagnosis.
ALS in the total sample correlated significantly with CTQ EA (r=.2O, P<.01) and diagnosis (r=.39, P<.01) but not gender (r=.O5, NS). In the BPD and female subgroups, the association of CTQ EA and ALS was no longer significant (r=.10, NS and r=.19, NS, respectively). AIM correlated significantly with C T Q EA in the total (r=.31, P<.01), OPD (r=.3O, P<.01) and male (r=.25, P<.01) subgroups but not for the female (r=.21, NS) or BPD (r=.15, NS) subgroups.
The correlation of AIM and ALS with each other ranged from 0.16-0.52 depending upon subgroup studied. BPD subjects demonstrated the lowest correlation (r=.16, NS) compared to a significant correlation in OPD subjects (r=.52, P<.01). We performed a z test of the difference between two independent correlations and found that the two coefficients are significantly different (z=2.43, P<.02).
The results of the series of hierarchical regression analyses using the dependent variables of ALS and AIM and variables of gender, diagnosis, CTQ EA score, and their interactions did not show evidence of a statistically significant interaction of gender, diagnosis, or their combination in the total sample. Similar analyses conducted solely within males, females, BPD patients, and OPD patients, similarly failed to reveal statistically significant interactions.
DISCUSSION
The magnitude of affective intensity as measured by the total AIM score in our BPD sample is somewhat lower than the level of 3.9 of another report examining hospitalized BPD patients. 12 The complete sample total AIM score is consistent with a value of 3.5 found in an overlapping sample of outpatient subjects with personality disorder 13 and suggests that moderate levels of affective symptomatology are present in these individuals. The participants in this study were part of a larger study examining biological parameters of personality disorder which required subjects to be free of potential confounds of medication, current substance abuse, or medical illness. For this reason, the sample may be somewhat unrepresentative of those with current active strong affective symptomatology, for example for those whose current BPD symptomatology would require hospitalization.
Our BPD sample experienced lower levels of sexual abuse than other BPD cohorts studied in the literature. Forty-five percent of the total sample and 51% of BPD subjects (female BPD 61% and male BPD 42%) endorsed any SA item. This contrasts with 71% of outpatient female BPD subjects 24 and 48% of outpatient male BPD subjects 25 endorsing histories of childhood SA. For BPD inpatients of mixed gender, rates as high as 62% to 75% 3149 have been reported. Our inclusion criteria may also have had an impact on this factor as well, leading to a selection bias against those with a history of sexual abuse, since they may be unable to do without medication and/or remain substance-free for 6 months.
This study yielded several important findings. First, in the total sample, ALS and AIM total scores did not appear to be significantly associated with self-report measures of childhood abuse or neglect except for emotional abuse.
In the OPD group, childhood EA is a significant predictor for AIM. In the BPD group, EA and gender are NS predictors of both ALS and AIM. When the BPD sample was examined by gender, we found no significant correlations for female or male BPD subjects with ALS, AIM, and CTQ EA.
These findings suggest that non-childhood variables, such as an inherited affective instability trait may be more important in the etiology of affective dyscontrol in BPD subjects. Whether this is influenced by the relative absence of childhood sexual trauma in this sample of subjects awaits further study. It is possible that childhood trauma is an unfortunate consequence of inherited affect instability traits in an infant with a caregiver whose own impulse control is already compromised and this combination evokes abuse, as it is possible that abuse negatively influences emotional regulation because of the effect trauma and stress have on the neurobiology of affect. Further study is definitely required.
The complicated differences between groups suggest that the relationship of ALS and AIM vary as a function of both gender and diagnosis and highlight the need to examine affective instability and trauma variables in future analyses by subgroup, even though in the present study none of the tests of the interaction terms were significant. Studies with additional BPD subjects and adequate power to analyze female and male OPD and BPD groups, could further delineate the importance of the subgroup differences we found here.
Our empirical findings using self-report measures of childhood abuse offer limited support to the theoretical notion that much of the psychopathology in BPD can be linked to emotional abuse rather than frank physical or sexual abuse. 2 ' 30 The special nature of the selection of the sample Volume 8 -Number 10 may have predisposed toward this finding and samples of patients with BPD and OPD with less current control over symptoms than the current sample may not confirm this implication. Studies examining the relationship of childhood trauma with other BPD characteristics, such as dissociation, also found correlations with BPD diagnosis 50 ' 51 and not with indices of childhood trauma.
" 52
The relationship of asymmetrical activation patterns in the prefrontal cortex and affect duration 1617 and the prefrontal cortex's inhibitory role of the amygdala 18 highlight the importance of this structure in emotional regulation. Recent findings of diminished serotonin responsivity in the prefrontal cortex of borderline subjects 5354 and recent report of increased activation of the amygdala in BPD 55 potentially link disturbed affect regulation with defining aspects of BPD phenomenology; impulsive aggression and behavioral dsycontrol.
Heritability for personality disorder in general is estimated at 0.60 and for BPD 0.69. 56 Statistically significant heritability estimates from twin studies 57 ' 63 exist for aggression, impulsivity, 576 ' and irritability, 5758 all traits that are inclusion criteria for the diagnosis of BPD. Whereas irritability is theorized to be the affective state that predisposes an individual to aggressive acts, 57 it may overlap conceptually with aspects of emotional instability. Heritability for affective lability has been estimated at 0.45 64 and for a higher order factor labeled emotional dysregulation, multivariate genetic analyses examining correlations between multiple traits within this construct, estimates heritability at 47%. 65 Such data highlight the need of continuing investigation into the genetic underpinnings of affective instability.
There are several limitations to this study. The ALS and AIM have not been well validated in personality disorder populations, and are relatively new measures attempting to assess a complex phenomenon. Other limitations include the validity of self-report measures in assessing past abusive experiences, particularly in a population of symptomatic individuals potentially prone to recall bias. There are data to support the verification of reported childhood events 6667 and stability of CTQ retrospective reporting in the context of differing levels of psychopathology. 68 Under-reporting 69 and overreporting 70 are still concerns. Structured childhood trauma interviews might yield more detailed responses. In a metaanalysis of 24 studies 71 exploring the relationship between traumatic experiences and a dissociation scale, however, there was no difference in effect size between studies that assessed trauma through interview or questionnaire. The possibility exists that with affective instability, structured childhood trauma interviews might yield more detailed responses.
CONCLUSION
These data indicate measures of affective instability are related to indices of self-reported childhood trauma only for emotional abuse, and this relationship varies as a function of gender and personality diagnosis. Within BPD, nontrauma factors may be more predominant in the etiology of affective Clinical manifestations of NMS are hyperpyrexia, muscle rigidity, altered mental status, and evidence of autonomic instability (irregular pulse or blood pressure, tachycardia, diaphoresis, and cardiac dysrhythmia). Additional signs may include elevated creatine phosphokinase, myoglobinuria (rhabdomyolysis), and acute renal failure. The diagnostic evaluation of patients with this syndrome is complicated. In arriving at a diagnosis, It is important to exclude cases where the clinical presentation includes both serious medical illness (e.g., pneumonia, systemic infection, etc) and untreated or inadequately treated extrapyramidal signs and symptoms (EPS). Other important considerations in the differential diagnosis include central anticholinerglc toxicity, heat stroke, drug fever, and primary central nervous system pathology. The management of NMS should include: 1) immediate discontinuation of antipsychotic drugs and other drugs not essential to concurrent therapy; 2) intensive symptomatic treatment and medical monitoring; and 3) treatment of any concomitant serious medical problems for which specific treatments are available. There is no general agreement about specific pharmacological treatment regimens for uncomplicated NMS. If a patient requires antipsychotic drug treatment after recovery from NMS, the potential reintroduction of drug therapy should be carefully considered. The patient should be carefully monitored, since recurrences of NMS have been reported. Tardtve Dyskinesia: A syndrome of potentially irreversible, involuntary, dysklnetic movements may develop in patients treated with antipsychotic drugs. Although the prevalence of the syndrome appears to be highest among the elderly, especially elderly women, it is impossible to rely upon prevalence estimates to predict, at the inception of antipsychotic treatment, which patients are likely to develop the syndrome. Whether antipsychotic drug products differ in their potential to cause tardive dyskinesia is unknown. The risk of developing tardive dyskinesia and the likelihood that it will become irreversible are believed to increase as the duration of treatment and the total cumulative dose of antipsychotic drugs administered to the patient increase. However, the syndrome can develop, although much less commonly, after relatively brief treatment periods at low doses. There is no known treatment for established cases of tardive dyskinesia, although the syndrome may remit, partially or completely, if antipsychotic treatment is withdrawn. Antipsychotic treatment, itself, however, may suppress (or partially suppress) the signs and symptoms of the syndrome and, thereby, may possibly mask the underlying process. The effect that symptomatic suppression has upon the long-term course of the syndrome is unknown. Given these considerations, ABILIFY should be prescribed in a manner that is most likely to minimize the occurrence of tardive dyskinesia. Chronic antipsychotic treatment should generally be reserved for patients who suffer from a chronic illness that (1) is known to respond to antipsychotic drugs, and (2) for whom alternative, equally effective, but potentially less harmful treatments are not available or appropriate. In patients who do require chronic treatment, the smallest dose and the shortest duration of treatment producing a satisfactory clinical response should be sought. The need for continued treatment should be reassessed periodically. If signs and symptoms of tardive dyskinesia appear in a patient on ABILIFY, drug discontinuation should be considered. However, some patients may require treatment with ABILIFY despite the presence of the syndrome. PRECAUTIONS General: Orthostatic Hypotension: Aripiprazole may be associated with orthostatic hypotension, perhaps due to its o^ -adrenergic receptor antagonism. The incidence of orthostatic hypotension associated events from five short-term, placebo-controlled trials in schizophrenia (n=926) on ABILIFY (aripiprazole) included: orthostatic hypotension (placebo 1 %, aripiprazole 1.9%); orthostatic lightheadedness (placebo 1%, aripiprazole 0.9%), and syncope (placebo 1%, aripiprazole 0.6%). The incidence of a significant orthostatic change in blood pressure (defined as a decrease of at least 30 mmHg in systolic blood pressure when changing from a supine to standing position) for aripiprazole was not statistically different from placebo (14% among aripiprazole-treated patients and 12% among placebotreated patients). Aripiprazole should be used with caution in patients with known cardiovascular disease (history of myocardial infarction or ischemic heart disease, heart failure or conduction abnormalities), cerebrovascular disease, or conditions which would predispose patients to hypotension (dehydration, hypovolemia, and treatment with antihypertensive medications). Seizure: Seizures occurred in 0.1% (1 /926) of aripiprazole-treated patients in short-term, placebo-controlled trials. As with other antipsychotic drugs, aripiprazole should be used cautiously in patients with a history of seizures or with conditions that lower the seizure threshold, e.g., Alzheimer's dementia. Conditions that lower the seizure threshold may be more prevalent in a population of 65 years or older. Potential tor Cognitive and Motor Impairment: In short-term, placebo-controlled trials, somnolence was reported in 11 % of patients on ABILIFY compared to 8% of patients on placebo; somnolence led to discontinuation In 0.1 % (1 /926) of patients on ABILIFY in short-term, placebo-controlled trials. Despite the relatively modest increased incidence of somnolence compared to placebo, ABILIFY, like other antipsychotics, may have the potentiai to impair judgment, thinking, or motor skills. Patients should be cautioned about operating hazardous machinery, including automobiles, until they are reasonably certain that therapy with ABILIFY does not affect them adversely. Body Temperature Regulation: Disruption of the body's ability to reduce core body temperature has been attributed to antipsychotic agents. Appropriate care is advised when prescribing aripiprazole for patients who will be experiencing conditions which may contribute to an elevation in core body temperature, e.g., exercising strenuously, exposure to extreme heat, receiving concomitant medication with anticholinergic activity, or being subiect to dehydration. Dysphagia: Esophageal dysmotility and aspiration have been associated with antipsychotic drug use. Aspiration pneumonia is a common cause of morbidity and mortality in elderly patients, in particular those with advanced Alzheimer's dementia. Aripiprazole and other antipsychotic drugs should be used cautiously in patients at risk for aspiration pneumonia (see PRECAUTIONS: Use in Patients with Concomitant Illness). SufacteThe possibility of a suicide attempt is inherent in psychotic illnesses, and close supervision of high-risk patients should accompany drug therapy. Prescriptions for ABILIFY should be written for the smallest quantity of tablets consistent with good patient management in order to reduce the risk of overdose.
Use in Patients with Concomitant Illness: Safety Experience in Elderly Patients with
Psychosis Associated with Alzheimer's Disease: In a flexible dose (2 to 15 mg/day), 10-week, placebo-controlled study of aripiprazole in elderly patients (mean age: 61.5 years; range: 56 to 95 years) with psychosis associated with Alzheimer's dementia, 4 of 105 patients (3.8%) who received ABILIFY died compared to no deaths among 102 patients who received placebo during or within 30 days after termination of the double-blind portion of the study. Three of the patients (age 92,91, and 87 years) died following the discontinuation of ABILIFY (aripiprazole) in the double-blind phase of the study (causes of death were pneumonia, heart failure, and shock). The fourth patient (age 78 years) died following hip surgery while in the double-blind portion of the study. The treatmentemergent adverse events that were reported at an incidence of >5% and having a greater incidence than placebo in this study were accidental injury, somnolence, and bronchitis. Eight percent of the ABIUFY-treated patients reported somnolence compared to one percent of placebo patients. In a small pilot, open-label, ascending-dose cohort study (n=30) in elderly patients with dementia, ABILIFY was associated in a dose-related fashion with somnolence. The safety and efficacy of ABILIFY in the treatment of patients with psychosis associated with dementia have not been established. If the prescriber elects to treat such patients with ABILIFY, vigilance should be exercised, particularly for the emergence of difficulty swallowing or excessive somnolence, which could predispose to accidental injury or aspiration. Clinical experience with ABILIFY in patients with certain concomitant systemic illnesses (see CLINICAL PHARMACOLOGY: Special Populations: Renal Impairment and Hepatic Impairment) is limited. ABILIFY has not been evaluated or used to any appreciable extent in patients with a recent history of myocardial infarction or unstable heart disease. Patients with these diagnoses were excluded from premarketing clinical studies.
Information for Patients:
Physicians are advised to consult full prescribing information to review issues to be discussed with patients for whom they prescribe ABILIFY. Drug-Drug Interactions: Given the primary CNS effects of aripiprazole, caution should be used when ABILIFY is taken in combination with other centrally acting drugs and alcohol. Due to its a* -adrenergic receptor antagonism, aripiprazole has the potential to enhance the effect of certain antihypertensive agents. Potential for Other Drugs to Affect ABIUFY: Aripiprazole is not a substrate of CYP1A1, CYP1A2, CYP2A6, CYP2B6, CYP2C8, CYP2C9, CYP2C19, or CYP2E1 enzymes. Aripiprazole also does not undergo direct glucuronidation. This suggests that an interaction of aripiprazole with inhibitors or inducers of these enzymes, or other factors, like smoking, is unlikely. Both CYP3A4 and CYP2D6 are responsible for aripiprazole metabolism. Agents that induce CYP3A4 (e.g., carbamazepine) could cause an increase in aripiprazole clearance and lower blood levels. Inhibitors of CYP3A4 (e.g., ketoconazole) or CYP2D6 (e.g., quinidine, fluoxetine, or paroxetine) can inhibit aripiprazole elimination and cause increased blood levels. Ketoconazole: Coadministration of ketoconazole (200 mg/day for 14 days) with a 15-mg single dose of aripiprazole increased the AUC of aripiprazole and its active metabolite by 63% and 77%, respectively. The effect of a higher ketoconazole dose (400 mg/day) has not been studied. When concomitant administration of ketoconazole with aripiprazole occurs, aripiprazole dose should be reduced to one-half of its normal dose. Other strong inhibitors of CYP3A4 (itraconazole) would be expected to have similar effects and need similar dose reductions; weaker inhibitors (erythromycin, grapefruit juice) have not been studied. When the CYP3A4 inhibitor is withdrawn from the combination therapy, aripiprazole dose should then be increased. Quinidine: Coadministration of a 10-mg single dose of aripiprazole with quinidine (166 mg/day for 13 days), a potent inhibitor of CYP2D6, increased the AUC of aripiprazole by 112% but decreased the AUC of its active metabolite, dehydro-aripiprazole, by 35%. Aripiprazole dose should be reduced to one-half of its normal dose when concomitant administration of quinidine with aripiprazole occurs. Other significant inhibitors of CYP2D6, such as fluoxetine or paroxetine, would be expected to have similar effects and, therefore, should be accompanied by similar dose reductions. When the CYP2D6 inhibitor is withdrawn from the combination therapy, aripiprazole dose should then be increased. Carbamazepine: Coadministration of carbamazepine (200 mg BID), a potent CYP3A4 inducer, with aripiprazole (30 mg QD) resulted in an approximate 70% decrease in Cmax and AUC values of both aripiprazole and its active metabolite, dehydro-aripiprazole. When carbamazepine is added to aripiprazole therapy, aripiprazole dose should be doubled. Additional dose increases should be based on clinical evaluation. When carbamazepine is withdrawn from the combination therapy, aripiprazole dose should then be reduced. No clinically significant effect of famotidine, valproate, or lithium was seen on the pharmacokinetics of aripiprazole (see CLINI-CAL PHARMACOLOGY: Drug-Drug Interactions). Potential for ABIUFY to Affect Other Drugs: Aripiprazole is unlikely to cause clinically important pharmacokinetic interactions with drugs metabolized by cytochrome P450 enzymes. In in vivo studies, 10-to 30-mg/day doses of aripiprazole had no significant effect on metabolism by CYP2D6 (dextromethorphan), CYP2C9 (warfarin), CYP2C19 (omeprazole, warfarin), and CYP3A4 (dextromethorphan) substrates. Additionally, aripiprazole and dehydro-aripiprazole did not show potential for altering CYP1A2-mediated metabolism in vitro (see CLINICAL PHARMACOLOGY: Drug-Drug Interactions). Alcohol: There was no significant difference between aripiprazole coadministered with ethanol and placebo coadministered with ethanol on performance of gross motor skills or stimulus response in healthy subjects. As with most psychoactive medications, patients should be advised to avoid alcohol while taking ABILIFY. Carcinogenesis, Mutagenesis, Impairment of Fertility: (Please see Full Prescribing Information).
Pregnancy Category C:
There are no adequate and well-controlled studies in pregnant women. It is not known whether aripiprazole can cause fetal harm when administered to a pregnant woman or can affect reproductive capacity. Aripiprazole should be used during pregnancy only if the potential benefit outweighs the potential risk to the fetus. Labor and Delivery: The effect of aripiprazole on labor and delivery in humans is unknown. Nursing Mothers: Aripiprazole was excreted in milk of rats during lactation. It is not known whether aripiprazole or its metabolites are excreted in human milk. It is recommended that women receiving aripiprazole should not breast-feed. Pediatric Use: Safety and effectiveness in pediatric and adolescent patients have not been established. Geriatric Use: Of the 5592 patients treated with aripiprazole in premarketing clinical trials, 659 (12%) were >65 years old and 525 (9%) were >75 years old. The majority (91 %) of the 659 patients were diagnosed with dementia of the Alzheimer's type. Placebo-controlled studies of aripiprazole in schizophrenia did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. There was no effect of age on the pharmacokinetics of a single 15-mg dose of aripiprazole. Aripiprazole clearance was decreased by 20% in elderly subjects (465 years) compared to younger adult subjects (18 to 64 years), but there was no detectable effect of age in the population pharmacokinetic analysis in schizophrenia patients. Studies of elderly patients with psychosis associated with Alzheimer's disease, have suggested that there may he a different tolerability profile in this population compared to younger pabents with schizophrenia (see PRECAUTIONS: Use in Patients with Concomitant Illness). The safely and efficacy of ABIUFY in the treatment of patients with psychosis associated with Alzheimer's disease has not been established. If the prescriber elects to treat such patients with ABILIFY, vigilance should be exercised.
ADVERSE REACTIONS
Aripiprazole has been evaluated for safety in 5592 patients who participated in multiple-dose premarketing trials in schizophrenia, bipolar mania, and dementia of the Alzheimer's type, and who had approximately 3639 patient-years of exposure. Adverse Findings Observed in Short-Term, Placebo-Controlled Trials of Patients with Schizophrenia The following findings are based on a pool of five placebo-controlled trials (four 4-week and one 6-week) in which aripiprazole was administered in doses ranging from 2 to 30 mg/day. Adverse Events Associated with Discontinuation of Treatment in Short-Term, Placebo-Controlled Trials: Overall, there was no difference In the incidence of discontinuation due to adverse events between aripiprazole-treated (7%) and placebo-treated (9%) patients. The types of adverse events that led to discontinuation were similar between the aripiprazole and placebo-treated patients. Adverse Events Occurring at an Incidence of >2% Among Aripiprazole-Treated Patients and Greater than Placebo in SnortTerm, Placebo-Controlled Trials: Treatment-emergent adverse events that occurred during acute therapy (up to 6 weeks) at an incidence of 2% or more of patients treated with aripiprazole (doses >2 mg/day) and for which the incidence was greater than the incidence reported for placebo were: Body as a Wholeheadache, asthenia, and fever; Digestive System-Nausea, vomiting, and constipation; Nervous System-anxiety, insomnia, lightheadedness, somnolence, akathlsia, and tremor; Respiratory System-rhinitis and coughing; Skin and
